Overview
Effects of Denosumab on Bone Microarchitecture After Total Knee Arthroplasty
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2023-12-31
2023-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study evaluates single dose of Denosumab in decreasing systemic and periprosthetic bone resorption after Total Knee Arthroplasty compared to placebo in 60 patients (30 placebo and 30 Denosumab) within 2 months after surgery. This study also evaluates the anti-RANKL effect of single dose of Denosumab in serum, skeletal muscle, synovium, fat, and cartilage.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
The Affiliated Hospital of Qingdao UniversityTreatments:
Denosumab
Criteria
Inclusion Criteria:Patients with Bilateral Knee Osteoarthritis treated with Staged Bilateral Total Knee
Arthroplasty, with an Interval of 8 weeks
Exclusion Criteria:
Patients allergies to Denosumab Patients with previous Osteoporosis treatment Patients with
renal failure Patients with previous Bisphosphonate treatment for more than 5 years
Patients failed to finish contralateral Total Knee Arthroplasty at 8 weeks